The votes in favor of Merck's shot are a sigh of relief after Kennedy gutted the panel and tapped replacements, some of whom are well-known vaccine critics.

Kennedy’s controversial panel overhaul met its first test. The result? A major win for public health ahead of RSV season. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who has ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.

RFK Jr.’s vaccine panel endorsed Merck’s RSV shot for babies, easing fears that his stance might delay rollout.

The shot, called clesrovimab and given the brand name Enflonsia, is made by Merck and joins two other interventions already on the market to protect babies against severe disease from RSV, a ...

ACIP's first meeting: Inside the unusual, RFK-appointed panel that's deciding on childhood vaccines Merck's shot is the second RSV monoclonal antibody of its kind on the market.

Merck plans to make ENFLONSIA available for ordering by physicians and health care administrators in July 2025, with shipments to be delivered before the start of the 2025-2026 RSV season.

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...